Asprosin Elisa kit - the Gospel of diabetes patients

12% SDS-PAGE analysis

Asprosin, a new type of glucose regulation protein hormone, can quickly induce glucose and regulate the release of glucose in the liver.
This hormone is a splicing product of the C terminal of profibrillin and is encoded by two exons of the FBN1 terminal.
Adipose tissue can produce and secrete Asprosin.
Asprosin circulates at nM levels, and single-dose recombinant Asprosin has biological activity that increases blood sugar and insulin concentrations.
Asprosin's target organ is the liver, which increases glucose release in liver cells by activating the g-protein - cAMP - PKA signaling pathway.
Asprosin is also associated with hyperinsulin-induced hyperactivity, and an increase in Asprosin content can lead to insulin resistance.
As a result, asprosin offers a target for treating type 2 diabetes and metabolism, providing scientists with a new type of diabetes therapy.

Recently published research papers on Cell, researchers from baylor college of medicine reveals a rare genetic disorder - type Neonatal premature aging disorder (NPS, Neonatal Progeroid Syndrome) is one of the major mechanisms, patients will accumulate in the body fat.
Relevant studies will have a significant impact on improving the health of neonatal progeria and type 2 diabetes.

As early as 2013, researchers have discovered a rare disease, the researchers Chopra, long-term commitment to energy metabolism disorders research, the whole genome sequencing to find the cause and exon group, the researchers Chopra, long-term commitment to energy metabolism disorders research, the study researchers found the cause of neonatal premature aging special genetic mutations, but how these mutations cause disease causes them it was not clear, then the researchers in the lab has carried on the related research, found that patients with these mutations can inhibit the body to produce a hormone of the unknown, and the hormone called asprosin seems can be produced by fat, when its circulation to the liver can guide the liver release glucose into the blood, and the body of the abnormal low asprosin NPS patients usually do not complete the above process, and the body typically show lower levels of low blood sugar and insulin.

Compared with the normal asprosin personal, hyperglycemia, obesity/diabetic individuals asprosin hormone levels higher insulin levels, and based on these information, the researchers decided to develop an antibody, can resist asprosin is the use of specific antibodies against asprosin, a process known as immune isolation, which could help reduce the release of glucose levels in patients with liver, so as to promote the pancreas cells release a small amount of insulin.

To test this theory, the researchers used a new antibodies to deal with the diabetic mice, found that a single dose of antibodies can be adjusted to normal mice in vivo insulin levels, if long-term treatment in mice, mice insulin resistance will be fully recovered.

Researchers said Chopra, the study shows that our entire process, we in this rare genetic disorder (neonatal premature aging disease) as the beginning, and then use the information can be found in patients with a new hormone, using hormones can be used in the treatment of many diseases;
If people with diabetes are resistant to asprosin-antibody responses and diabetic mice, this study may help scientists develop a new type of treatment for diabetes.
Another highlight of this article is helping scientists understand the mechanisms of rare genetic diseases.

prev:What is the Asprosin?(2017-08-15)

next:Asprosin - II a new target for type diabetes treatment(2017-08-16)